A 62-year-old white male, with a bipolar disorder treated with lithium, a history of type II diabetes mellitus, and hypertension, was referred to the renal clinic for evaluation of nephrotic syndrome and stage IV chronic kidney disease (CKD) (Modification of Diet in Renal Disease glomerular filtration rate 26 cc/min/1.73 m 2 ). The patient had a history of bipolar disorder treated for over 10 years with lithium until 2 years ago when a diagnosis of nephrogenic diabetes insipidus and mild CKD was made and lithium discontinued. At that time, he had a urine osmolality of 272 mOsm/kg and a serum creatinine of 1.5 mg/dl. His medications included lisinopril, atenolol, gemfibrozil, haloperidol, quetiapine, metformin, and bupropion SR. There was no history of polyuria or polydipsia. Review of systems revealed no other significant symptoms. On examination, blood pressure was 133/64 mm Hg, heart rate 70 beats per minute, regular rhythm. Lung and cardiovascular examination were unremarkable. Abdomen was soft, nontender with no organomegaly. Extremities revealed trace edema. Urine examination revealed a specific gravity of 1.012, pH 5.5, 3 þ protein, negative blood and no casts. His urine albumin creatinine ratio 3 months before was 3.9 g protein per gram creatinine. His laboratory investigations revealed BUN 40 mg/dl (reference range 9-25 mg/dl), creatinine 3.0 mg/dl (0.7-1.3 mg/dl), potassium 5.6 mEq/l (3.5-5.0 mmol/l), glucose 72 mg/dl (5-118 mg/dl), HbA1C 4.8 (4.2-5.8%), serum total proteins 6.2 g/dl (6-8 g/dl), albumin 3.5 g/dl (3.7-5.4 g/dl), cholesterol 208 mg/dl (140-199 mg/dl), triglycerides 626 mg/dl (35-150 mg/dl), low-density lipoprotein 78 mg/dl (50-129 mg/dl), hemoglobin 13.2 g/dl (11.5-16.4 g/dl), and hematocrit of 37.7% (36-48%). Complements and other serologic tests were negative. Renal ultrasound revealed bilateral nephromegaly (right kidney 12.6 cm and left kidney 12.9 cm) with a diffuse increase in echogenicity and innumerable tiny cysts throughout the kidney (cortex and medulla) (Figure 1 ). There was no evidence of hydronephrosis. A clinical diagnosis of nephrotic syndrome was made and it was decided to proceed to a kidney biopsy.
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KIDNEY BIOPSY
On light microscopy, 16 glomeruli were observed. Seven (44%) were globally sclerosed and two revealed segmental capillary collapse, with hyaline entrapment and adhesion of the tuft to the Bowman's capsule ( Figure 2 ). The remaining glomeruli showed a normal architecture, with mild mesangial hypercellularity associated with diffuse increase in the extracellular matrix. The glomerular basement membranes revealed focal irregularities and short segments with double contours. Tubules revealed extensive atrophy (45%) with thickening of tubular basement membranes. Many micro cysts, ranging in size from 1 to 2 mm, were noted. These were localized in the cortex and along the corticomedullary junction. The lining was of low cuboidal epithelial cells. Pericystic stromal fibrosis was apparent ( Figure 3 ). Focal calcification and protein reabsorption granules were also noted in many tubules. The interstitium showed prominent areas of fibrosis (45%) and interstitial inflammation by mononuclear cells and very rare polymorphonuclear cells. Interlobular arteries and arterioles revealed moderate changes of arteriosclerosis. Congo-red stain was negative. No significant deposits were observed on immunofluorescence microscopy, except for nonspecific trapping of immunoglobulin M and C3 in the mesangial areas. Tubular basement membranes revealed focal deposition of C3 ( þ þ þ /4 þ ). A single sclerosed glomerulus was observed on semithin sections hence the tissue was not examined at ultrastructural level.
A biopsy diagnosis of chronic active interstitial nephritis likely secondary to lithium toxicity was made. The presence of numerous cortical micro cysts and the focal global and segmental glomerulosclerosis (FSGS) were also attributed to lithium.
of his lisinopril dose. However, at the last follow-up, the patient's kidney function as measured by serum creatinine was 3.52 mg/dl with an estimated Modification of Diet in Renal Disease glomerular filtration rate of 18 ml min À1 1.73 m À2 . His urine protein to creatinine ratio was 5.4 g protein per gram creatinine.
DISCUSSION
Chronic forms of lithium toxicity include renal tubular acidosis, chronic tubulointerstitial nephritis, and nephrotic syndrome. Our patient illustrates many of these changes. He developed nephrogenic diabetes insipidus (NDI) following lithium therapy, which was subsequently complicated by the development of chronic progressive kidney disease; this necessitated the discontinuation of lithium. The patient also presents with the nephrotic syndrome, most likely secondary to FSGS, as a consequence of lithium exposure. His kidney biopsy revealed the presence of extensive chronic interstitial nephritis, tubular microcystic structures in the renal cortex and FSGS that are characteristic, but not specific for lithium toxicity.
Lithium carbonate is a valuable therapeutic agent in the treatment of manic-depressive illness. It continues to be widely used. However, lithium has a narrow therapeutic index and can result in considerable toxicity. Both acute and chronic forms of renal toxicity are well-known complications. 1, 2 The major complications of lithium toxicity are discussed.
Nephrogenic diabetes insipidus
The first report of lithium toxicity in humans was made by Edgell et al.
2 approximately 3 decades ago. The most common early complication of chronic lithium ingestion is NDI, which is observed in approximately 20% of patients. 1 NDI occurs because of lithium accumulation in collecting tubule cells through entry of lithium via sodium channels in the luminal membrane. 3 Lithium interferes with the ability of antidiuretic hormone to increase water permeability. Several mechanisms have been postulated, including decreased stimulation of adenylate, reduced density of antidiuretic hormone receptors, and a downregulation of aquaporin-2, the collecting tubule water channel. [4] [5] [6] [7] The progression of the renal concentrating deficit is usually observed early-within the first few years of treatment. 8 Although it has been suggested that the lesion of lithium-induced tubular toxicity is reversible in its earliest stages, 1 there is a 'point-of-noreturn' after which injury becomes irreversible.
9,10 Our patient developed irreversible damage from lithium as evidenced by the persistent clinical abnormalities and the findings on his renal biopsy. 
Lithium associated chronic tubulointerstitial nephritis
Chronic lithium-induced tubulointerstitial nephritis is characterized by the presence of tubular atrophy and interstitial fibrosis. 11 Chronic interstitial changes on renal biopsy have been described even following acute intoxication or NDI. 12 The presence of tubular cysts, as observed with our patient, is highly characteristic of lithium toxicity. 13 Markowitz et al.
11
documented cysts in 62.5% of the biopsies studied and confirmed, in elegant immunohistochemical and lectin studies, that the tubular cysts are predominantly of distal and collecting tubular origin. These micro cysts can also be detected using magnetic resonance imaging or ultrasound. Indeed, in their magnetic resonance imaging study of 16 patients on long-term lithium therapy, Farres et al.
14 have demonstrated abundant, uniform, symmetrically distributed renal micro cysts in normal-sized kidneys. In our patient, micro cysts were observed by ultrasound in relatively large kidneys ( Figure 1 ).
Lithium induced glomerular damage
Proteinuria is an uncommon manifestation of lithium toxicity and is usually not severe (24-h protein excretion o1 g day
. 15 Lithium-induced nephrotic syndrome has been reported but is rare, with only 26 cases reported in the literature. 11, [15] [16] [17] [18] The mechanism of injury is thought to be lithium-induced epithelial toxicity, resulting in either minimal change disease or secondary FSGS. Minimal change disease is more common than FSGS. 19 Tam et al. 20 have invoked a role for lithium as a modulator of the phosphoinositol pathway in the pathogenesis of minimal change disease following lithium therapy. In some patients with minimal change disease, resolution after discontinuation of lithium therapy and relapse after re-introduction of lithium has been reported, showing a causative link with lithium therapy. 21 FSGS in patients following chronic lithium therapy has also been reported in the literature. 11, 15, 16 Markowitz et al. 11 have described FSGS in 50% of their 24 cases. Glomerulomegaly and a variable degree of foot process fusion is a consistent finding. A higher prevalence of glomerular changes correlated with a higher prevalence of proteinuria. Significant proteinuria (43 g day
À1
) was observed in 6 of the 24 (25%) and nephrotic syndrome in three patients (12.5%). In the patient we present here, we were unable to definitively evaluate the degree of podocyte injury because insufficient material was available for ultrastructural examination. Therefore, we cannot say for sure whether this patient truly had secondary FSGS either from direct damage by lithium or hyperfiltration injury, or whether he had a primary form of FSGS.
Lithium and chronic kidney disease
Lithium's role as a causal agent in progressive chronic kidney disease (CKD) is controversial. Johnson 22 suggests that lithium-induced CKD is rare. Coskunol et al. compared 107 subjects on lithium therapy with a matched psychiatric control population. They found no relationship between creatinine clearances and duration of illness, duration of lithium treatment and daily lithium dosages. 23 Boton et al.,
1 from their analysis of several published studies, estimated that 15% of patients displayed only mild reduction in glomerular filtration rate. Hansen et al. 13 reported an increase in serum creatinine of 40.3 mg/dl in eight patients treated with lithium for at least 4 1/2 years. Jorkasky et al. 24 have reported a significant decline in renal function within 1 year of therapy in their prospective study of lithium-induced nephropathy. Presne et al. 25 have demonstrated the annual loss of creatinine clearance in patients to be 2.9 ml min À1 among 54 patients with lithium-induced nephropathy, and claimed that the renal disease was slowly progressive and was related to the duration of lithium administration. Markowitz et al.
11 observed a high prevalence of CKD in the 24 subjects in their study (mean serum creatinine of 2.8 mg/dl, range 1.3-8 mg/dl) and found that serum creatinine at the time of biopsy was the only reliable predictor of progression to endstage renal disease. In their study, progression of kidney disease to end-stage renal disease was observed in 8 of 9 patients with serum creatinine 42.5 mg/dl at the time of diagnosis as compared to 1 of 10 patients with a serum creatinine o2.5 mg/dl.
Lithium dosing and kidney function
Different treatment regimes have been evaluated. Once-daily regimes appear to be less toxic than multiple-daily dose schedules, 26, 27 perhaps because of the possibility of renal tubular regeneration with a once-daily dosing schedule. On the other hand, patients who have switched from one regime to another have not demonstrated a significant change in tubular function, except when the switch occurred within less than 5 years of treatment. 28 Other risk factors for kidney progression include age, episodes of lithium intoxication, and current drug administration. 29 The concomitant presence of co-morbid disorders such as hypertension, mitral valve insufficiency, hyperparathyroidism, hyperuricemia, diabetes have also been reported to be important. 9, 10, 30 Aggravation of diabetic nephropathy by lithium has also been reported. 31 The concomitant use of other anti-psychotic drugs in exacerbating lithium-induced injury has been discussed in the literature. 10, 32 Acute lithium intoxication. Acute lithium intoxication is a frequent complication of chronic lithium therapy because of its narrow therapeutic index. It is critical to recognize the clinical manifestations of acute lithium toxicity because the mortality rate is reported to be approximately 25% in an acute overdose and 9% in patients intoxicated during maintenance therapy. 33 Since lithium primarily undergoes renal excretion, factors that affect glomerular filtration rate and reabsorption play an important role in maintaining serum lithium levels. Patients with lithium intoxication may present with a variety of clinical manifestations, including gastrointestinal, cardiac, renal, endocrine, and neurological symptoms. Neuropsychiatric symptoms are particularly common: characteristic findings include neuromuscular excitability, irregular coarse tremors, fascicular twitching, rigid motor agitation, muscle weakness, ataxia, sluggishness, and delirium. Non-neurologic presenting features include nausea, vomiting, diarrhea, leukocytosis, sinus bradycardia, and hypotension. Severe lithium intoxication can result in seizures, stupor, coma, and a 10% risk of permanent neurologic sequelae (such as dementia and ataxia). Kidney manifestations include polyuria and polydipsia, which is important pathogenically as polyuria may lead to volume depletion and decreased fractional excretion of lithium.
Management of lithium therapy and toxicity
A multifaceted approach to the management of lithium therapy is essential-prevention of toxicity as well as treating those who develop NDI. Strategies to reduce the risk of lithium toxicity include careful lithium dosing with regular monitoring of blood levels. This is especially important since lithium has a narrow therapeutic index and toxicity has been observed even among those patients at supposedly therapeutic doses. Therapeutic levels of lithium are between 0.6 and 1.2 mEq/l. Mild toxicity with lithium is usually observed at a plasma lithium level of 1.5-2.5 mEq/l and moderate toxicity at lithium levels of 2.5-3.5 mEq/l. Another important component of preventing lithium toxicity is to carefully monitor patients; in this regard, looking for symptoms of polyuria and excessive thirst and assessment of kidney function, urine volume, and/or urine osmolality are important. Finally, preventing volume depletion is important in reducing the risk of lithium toxicity. Bendz and Aurell 34 suggest monitoring plasma lithium and plasma creatinine assessment every 4 months. Thyroid and parathyroid function, weight, 24 h consumption of liquids (24-h urine output), blood glucose and blood pressure are be monitored annually. These authors also recommend testing for tubular and glomerular functions every 5 years while the patient is on lithium therapy and when clinically indicated.
The treatment of an acute intoxication from any drug requires rapid evaluation, including the recognition that poisoning has occurred, identification of the agents involved, assessment of severity, and prediction of toxicity. Management, consisting of supportive care, prevention of drug absorption, and, when appropriate, the administration of antidotes and enhancement of drug elimination is critical. The key aspects of managing acute lithium toxicity include aggressive volume resuscitation, gastric lavage with polyethylene glycol to prevent the continued absorption of lithium, and hemodialysis. Hemodialysis is generally indicated in two clinical scenarios: a plasma lithium level 44 mEq/l, regardless of the clinical status of the patient, and the plasma lithium concentration 42.5 mEq/l in a patient who is markedly symptomatic or with underlying CKD that might limit urinary lithium excretion. 33, 35 In the treatment of NDI, lithium discontinuation is recommended; however, the lithium-concentrating defect may be permanent after prolonged lithium usage. Slowing progression using an angiotensin blocker, control of blood pressure, and avoiding other nephrotoxins are also recommended. (The use of amiloride should be considered in those patients where lithium therapy cannot be discontinued.)
Conclusions
The patient we have presented highlights several unusual features associated with lithium therapy: chronic tubulointerstitial nephritis and microcystic changes, nephrotic range proteinuria with associated focal and global glomerulosclerosis, and the presence of CKD. Lithium toxicity can present with several faces: acute abnormalities from lithium poisoning and chronic changes such as NDI, epithelial cell disease, and CKD. While lithium is a boon in the management of bipolar disorders, it has unfortunately undesirable side effects and lithium therapy could be likened to a 'double-edged sword-it cuts both ways.'
